Scilex Holding Company (SCLX)

Market Cap	36.23M
Revenue (ttm)	56.59M
Net Income (ttm)	-72.81M
Shares Out	5.24M
EPS (ttm)	-21.33
PE Ratio	n/a
Forward PE	1.52
Dividend	n/a
Ex-Dividend Date	n/a

Volume	171,162
Open	6.72
Previous Close	0.19
Day's Range	6.20 - 7.64
52-Week Range	6.13 - 80.50
Beta	1.05
Analysts	Strong Buy
Price Target	11.33 (+63.73%)
Earnings Date	May 12, 2025

About SCLX

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of ...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2011
• Employees: 115
• Stock Exchange: NASDAQ
• Ticker Symbol: SCLX
• Website: https://www.scilexholding.com

Financial Performance

In 2024, Scilex Holding Company's revenue was $56.59 million, an increase of 21.07% compared to the previous year's $46.74 million. Losses were -$72.81 million, -56.40% less than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for SCLX stock is "Strong Buy." The 12-month stock price forecast is $11.33, which is an increase of 63.73% from the latest price.

Price Target

$11.33

(63.73% upside)

Analyst Consensus: Strong Buy